InspireMD Inc (NYSE: NSPR), which is best known for having developed the CGuard Embolic Prevention System for preventing strokes triggered by carotid artery disease, has seen its stock perform impressively this year so far.
The stock has gained as big as 125% so far this year and this morning, it is again on the move. It has gained as much as 10% this morning and it could be the stock to watch for investors at this point. This morning the company announced that it has hired the services of Hart Clinical Consultants to conduct the clinical trial of its product CGuard Carotid Stent System.
Hart Clinical Consultants is one of the leaders among Contract Research Organizations and the trial in question is going to be conducted in the United States. It is a key appointment from InspireMD and it has naturally led to considerable excitement about the stock. Investors could consider adding it to their watch lists at this point.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.